What is NIFTYTM?
NIFTYTM is a highly accurate, Non-Invasive Prenatal Screening (NIPS) test for detecting genetic abnormalities including Trisomies, Deletion Syndromes and Sex Chromosome Aneuploidies.
NIFTYTM uses a blood sample from the pregnant mother to analyse the fetal DNA for chromosomal conditions, such as Down Syndrome (Trisomy 21) and Edwards Syndrome (Trisomy 18), from as early as 10 weeks of pregnancy. Gender determination is also available at no additional cost.
How does NIFTYTM work?
Cell-free DNA fragments (cfDNA) are short fragments of DNA which can be found circulating in the blood. During pregnancy, cfDNA fragments from both the mother and fetus are present in the maternal blood. The NIFTYTM test requires taking a blood sample from the mother, which is then analysed to detect chromosomal abnormalities in the fetus. Please note that a qualified person is required to collect the sample via a standard medical blood draw.
Our laboratory uses whole genome sequencing to analyse the fetal DNA. The entire genome is sequenced and compared against optimal reference chromosomes to accurately determine the presence of genetic abnormalities. Using this methodology, the NIFTYTM test is able to produce highly accurate results and screen for a broader range of abnormalities, including trisomy, sex chromosomal aneuploidy and deletion/duplication syndromes.
Why Should I Choose Non-Invasive Prenatal Screening?
Many prenatal screening options already exist. However, compared to NIFTYTM, traditional screening methods have lower accuracy and higher false positive rates (as shown in the images below).
A false positive is where you receive a positive result for a test, when you should have received a negative result. NIFTYTM has a false positive rate of 0.05% only, which is much lower than other screening methods.
Invasive diagnostic tests, such as amniocentesis or chorionic villus sampling (CVS) are accurate but also carry a 1 – 2% risk of miscarriage. NIFTYTM is considered 100% safe for both the mother and unborn baby, as all that is required for testing is a 10ml maternal blood sample.
NIFTYTM is the most validated prenatal screening test on the market. NIFTYTM has a sensitivity greater than 99% from a study of nearly 147,000 pregnancies, and to date over 3 million tests have been carried out worldwide. You can read all the NIFTY® test’s published clinical data at www.niftytest.com/healthcare-providers/clinical-data/